2019-10-29 16:00Financial Performance - Net profit attributable to shareholders was ¥124,880,496.24, a decrease of 39.59% year-on-year[8]. - Operating revenue for the period was ¥1,010,151,349.28, down 10.10% compared to the same period last year[8]. - Basic earnings per share were ¥0.1001, reflecting a decrease of 39.59% year-on-year[8]. - The company's net profit for the first three quarters of 2019 reached ¥656,581,519.69, representing a 53.07% increase compared to the same period last year[25]. - Investment income increased significantly to ¥511,993,974.31, a 372.78% rise year-on-year, due to the change in accounting method for certain investments[25]. - The company's operating profit rose by 45.92% to ¥774,270,632.09, driven by higher investment income despite a decrease in gross profit margin[25]. - The total comprehensive income attributable to the parent company was CNY 201,138,781.85, compared to CNY 238,601,956.67 in the previous period, indicating a decrease in overall profitability[86]. - The net profit for the current period is approximately ¥109.51 million, representing a growth of 5.3% compared to ¥103.53 million in the previous period[91]. - The net profit attributable to the parent company for the current period is approximately ¥671.28 million, an increase of 48.8% from ¥450.88 million in the previous period[100]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥14,807,436,125.37, an increase of 8.44% compared to the end of the previous year[8]. - Non-current assets totaled ¥9,273,462,422.62, an increase of 15.1% from ¥8,055,062,473.35[62]. - Total liabilities decreased by 32.54% to ¥670,983,378.72, influenced by the reclassification of certain bonds to current liabilities[25]. - Current liabilities increased to ¥5,478,637,612.73, compared to ¥4,504,473,454.26, marking a rise of 21.6%[65]. - The company's equity attributable to shareholders rose to ¥6,834,565,368.94, up from ¥6,068,025,668.64, representing an increase of 12.6%[68]. - Total liabilities increased to CNY 4,557,432,820.89, compared to CNY 4,376,587,436.51 in the previous period, indicating a rise in financial obligations[78]. - Total assets reached approximately ¥13.66 billion, a decrease of ¥120.73 million compared to the previous period[137]. - Current assets totaled approximately ¥5.6 billion, with a slight decrease of ¥37.56 million from the previous period[137]. Cash Flow - The net cash flow from operating activities was ¥34,972,944.05, a significant decline of 90.43%[8]. - Cash flow from operating activities showed a net outflow of ¥151,455,011.02, a 130.64% decline compared to the previous year, attributed to increased cash payments for goods and services[29]. - The net cash flow from investing activities was negative at ¥638,696,357.83, a 79.58% increase in outflow year-on-year due to higher cash payments for equity investments[29]. - Cash flow from operating activities totaled 1,682,827,555.79 yuan, an increase from 1,308,163,122.91 yuan in the previous period, indicating improved operational performance[123]. - The cash flow from investment activities resulted in a net outflow of -1,923,296,357.10 yuan, compared to -1,547,193,114.80 yuan in the previous period, indicating increased investment expenditures[123]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,198[12]. - The largest shareholder, Shenzhen Le Ren Technology Co., Ltd., held 38.01% of the shares, totaling 474,029,899 shares[12]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[18]. - The company has committed to not engaging in any competitive business during the period of being a controlling shareholder[41]. Research and Development - Research and development expenses surged to CNY 54,048,691.20, compared to CNY 6,445,554.94 in the previous period, reflecting a significant increase in investment in innovation[79]. - Research and development expenses increased significantly to ¥18.67 million, up 112.5% from ¥8.79 million in the previous period[91]. - The company is advancing its clinical trials for the monoclonal antibody drug AR-301, which has received approval for Phase III trials from NMPA and is also undergoing trials in the US and Europe[30]. - The company continues to advance the RVX-208 project based on the clinical trial results, with major clinical outcomes to be announced at the American Heart Association meeting[33]. Financial Instruments and Standards - The company executed new financial instrument standards, leading to various reclassifications in financial assets[23]. - The company has implemented new financial instrument standards effective from January 1, 2019, impacting the classification of certain financial assets[147].